Tagged with M

Americas After five years in China, Rogier Janssens goes on to lead Latin America Healthcare for EMD Serono. Rogier Janssens, former General Manager of the biopharma business of Merck KGaA, Darmstadt, Germany in China has been appointed Senior Vice President – Head of Latin America Healthcare for EMD Serono, taking over…

Europe Organon’s general manager for Spain and Portugal, Juan Vera, explains the challenges of executing the spinoff from MSD in the middle of the pandemic, the reasons why his affiliate has become the largest in Europe by revenue and the fourth globally after the US, China and Japan. In addition, Vera…

Europe Merck Sharp & Dohme (MSD) Spain’s Ana Argelich Hesse comments on how the big changes experienced by the global organization in 2021, including a new CEO and the spinoff of Organon, have impacted the American giant’s local strategy. Argelich Hesse also discusses regulatory changes in the Spanish market, Spain’s importance…

United Kingdom Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association of the British Pharmaceutical Industry (ABPI) has appointed a new president who will take on the plan.  The Association of…

Olympus Olympus is a 100-year-old technology company that has revolutionised the world of cameras since 1919, and recently underwent a transformation shifting its focus entirely to MedTech. Ronald Boueri, Regional Division Manager for Middle East and Africa region sheds light on the company presence regionally, as well as efforts to position…

Egypt Four years after Egypt enacted a new universal health law, the country’s pharmaceutical market has consolidated itself as the fastest growing in the Middle East and Africa, far outpacing Saudi Arabia, South Africa, the UAE and Algeria. With USD 6.3 billion in value, Egyptian pharma is about to double its…

AAM Dan Leonard, President and CEO of the Association for Accessible Medicines (AAM) and Erik C. Komendant, the organisation’s Senior Vice President of Government Affairs, spoke to us about drug pricing issues in the United States and where the AAM stands with respect to the Biden administration’s initiatives to make medicines…

WHO Representatives from the US FDA, EMA, WHO and the pharma industry debated over the possible inclusion of environmental impact in future good manufacturing practice (GMP) inspections of drug production sites and the need for a new type of relationship between companies and regulators. We need more information and data to…

Europe The new president of Medicines for Europe, Elisabeth Stampa, outlines one of the priorities of her mandate: working to adjust the EU pharma policy framework to improve access for patients across Europe.    Regulatory flexibilities implemented during COVID-19 showed that the EU system can require one of highest safety, quality…

Switzerland Lonza’s global head of Mammalian Biologics, Jennifer Cannon, talks about disruption in the CDMO industry, explains how the Swiss giant is reimagining new models based on risk-sharing, and goes through the effects of the pandemic on both the company and the industry, including supply chain disruption, demand for new capabilities…

Ichnos Cyril Konto, President & CEO of Ichnos Sciences comments on the company’s unique approach to finding new cancer treatments, the possibility of becoming fully independent from parent company Glenmark Pharmaceuticals and the licensing agreement Ichos has with Almirall for the IL-1RAP antagonist, ISB 880. … the Ichnos team has further…

North America In April, the Canadian Ministry of Health announced the government would not be proceeding with certain proposed amendments to the Patented Medicines Regulations which govern the Patented Medicine Prices Review Board (PMPRB)—amendments related to new excessive price factors. The decision, well-received by Innovative Medicines Canada, came after these controversial economic…